Pretreatment serum GFAP levels were not significantly associated with postoperative oncological outcomes, possibly because the number of cells expressing GFAP is inversely proportional to the extent of anaplasia, and loss of GFAP expression is frequently observed in high-grade gliomas [32]. This evidence concerns the gene GFAP and glioma.